Raynaud's phenomenon

Research output: Contribution to journalArticlepeer-review

Abstract

Raynaud's phenomenon is a common clinical problem occurring in 3% to 5% of the general population. The first symptom of scleroderma is often Raynaud's phenomenon, which is associated with a diffuse small vessel vasculopathy, and ischemia and reperfusion injury to skin and other organs targeted in this disease. Current studies support the concept that Raynaud's phenomenon is secondary to a local defect in the regulation of regional blood flow. New evidence demonstrates that there is a profound sensitivity to α2-adrenoceptors mediated vasoconstriction in scleroderma vessels. Traditional treatment of Raynaud's phenomenon is cold avoidance and the use of vasodilators. Oral prostaglandins have shown promise as therapeutic agents.

Original languageEnglish (US)
Pages (from-to)765-781
Number of pages17
JournalRheumatic Disease Clinics of North America
Volume22
Issue number4
DOIs
StatePublished - 1996

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Raynaud's phenomenon'. Together they form a unique fingerprint.

Cite this